The present invention relates to a diagnostic device (400) for measuring component performance on an automated radiopharmaceutical synthesis device (50).

The present invention relates to an automated radiosynthesis device adapted for the addition of multiple additional components. The automated radiosynthesis device of the invention enables a wider range of radiochemical synthetic processes to be carried out in an automated fashion.

The automated synthesis of clinically relevant amounts of 16-.sup.18F-fluoro-5-dihydrotestosterone (.sup.18F-FDHT) using a commercially available radiosynthesizer. Synthesis was performed in 90 minutes with a decay-corrected radiochemical yield of 295%. The specific activity was 4.6 Ci/mol (170 GBq/mol) at end of formulation with a starting activity of 1.0 Ci (37 GBq). The formulated .sup.18F-FDHT yielded sufficient activity for multiple patient doses and passed all quality control tests required for routine clinical use.

Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients, are provided. Certain of the systems and methods described herein are capable of manufacturing multiple chemical products without the need to fluidically connect or disconnect unit operations when switching from one making chemical product to making another chemical product.

A convection-free flow-type reactor includes a reactor body. The reactor body includes a reaction chamber to house a fluid. An inlet is in communication with the reaction chamber to allow input of a reactant fluid. An outlet is in communication with the reaction chamber to allow output of a product fluid. An energy beam source device provides an energy beam to irradiate the reactant fluid in the reaction chamber. The disclosure further provides a convection-free flow-type synthesis method.

The present invention relates to an automated radiosynthesis device adapted for enhanced automatic disconnection of a disposable kit once a radiosynthesis has been carried out. The automated radiosynthesis device of the invention therefore reduces the time to remove the disposable kit from the radiosynthesis device and reduces radiation exposure to the operator.

The automated synthesis of clinically relevant amounts of 16-.sup.18F-fluoro-5-dihydrotestosterone (.sup.18F-FDHT) using a commercially available radiosynthesizer. Synthesis was performed in 90 minutes with a decay-corrected radiochemical yield of 295%. The specific activity was 4.6 Ci/mol (170 GBq/mol) at end of formulation with a starting activity of 1.0 Ci (37 GBq). The formulated .sup.18F-FDHT yielded sufficient activity for multiple patient doses and passed all quality control tests required for routine clinical use.

Systems and methods are disclosed for synthesizing one or more simple alcohols from mixtures including organic acids, water, and a superparamagnetic catalyst exposed to fluctuating magnetic fields under ambient conditions.